[go: up one dir, main page]

IL131349A - תכשירים פרמצבטים המכילים קינזולינון למניעת נאו- וסקולריזציה ולטיפול בגידולים - Google Patents

תכשירים פרמצבטים המכילים קינזולינון למניעת נאו- וסקולריזציה ולטיפול בגידולים

Info

Publication number
IL131349A
IL131349A IL13134998A IL13134998A IL131349A IL 131349 A IL131349 A IL 131349A IL 13134998 A IL13134998 A IL 13134998A IL 13134998 A IL13134998 A IL 13134998A IL 131349 A IL131349 A IL 131349A
Authority
IL
Israel
Prior art keywords
group
halofuginone
hydrogen
compound
tumor
Prior art date
Application number
IL13134998A
Other languages
English (en)
Other versions
IL131349A0 (en
Inventor
Nagler Arnon
Pines Mark
Original Assignee
Israel State
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Israel State, Hadasit Med Res Service filed Critical Israel State
Publication of IL131349A0 publication Critical patent/IL131349A0/xx
Publication of IL131349A publication Critical patent/IL131349A/he

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL13134998A 1997-02-11 1998-02-11 תכשירים פרמצבטים המכילים קינזולינון למניעת נאו- וסקולריזציה ולטיפול בגידולים IL131349A (he)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/797,703 US6028075A (en) 1997-02-11 1997-02-11 Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
PCT/IL1998/000070 WO1998034613A1 (en) 1997-02-11 1998-02-11 Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Publications (2)

Publication Number Publication Date
IL131349A0 IL131349A0 (en) 2001-03-19
IL131349A true IL131349A (he) 2004-08-31

Family

ID=25171574

Family Applications (1)

Application Number Title Priority Date Filing Date
IL13134998A IL131349A (he) 1997-02-11 1998-02-11 תכשירים פרמצבטים המכילים קינזולינון למניעת נאו- וסקולריזציה ולטיפול בגידולים

Country Status (11)

Country Link
US (3) US6028075A (he)
EP (1) EP1007044B1 (he)
JP (1) JP2001518075A (he)
KR (1) KR100518106B1 (he)
AT (1) ATE367158T1 (he)
AU (1) AU738516B2 (he)
CA (1) CA2280850C (he)
DE (1) DE69838099T2 (he)
ES (1) ES2290983T3 (he)
IL (1) IL131349A (he)
WO (1) WO1998034613A1 (he)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
JP2001518062A (ja) * 1997-03-31 2001-10-09 農務省 農務調査機構 肺繊維症の治療
DE69927987T2 (de) * 1998-08-13 2006-11-09 Hadasit Medical Research Services & Development Co. Ltd. Hemmung von mit gewebetrauma verbundenen pathogenen prozessen
IL148246A0 (en) * 1999-09-09 2002-09-12 Hadasit Med Res Service Promotion of wound healing
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
WO2002086078A2 (en) * 2001-04-23 2002-10-31 University Of Virginia Patent Foundation Synthesis and evaluation of novel phthalimide mimics as anti-angiogenic agents
CA2459583A1 (en) * 2001-09-05 2003-03-13 Minerva Biotechnologies Corporation Compositions and methods of treatment of cancer
JP2005501887A (ja) * 2001-09-05 2005-01-20 ミナーヴァ・バイオテクノロジーズ・コーポレーション 癌の処置における組成物およびその使用
IL147416A (en) * 2001-12-31 2008-11-26 Israel State Combined modalities for improved cancer treatment
IL148292A (he) * 2002-02-21 2008-08-07 Shai Yarkoni תכשירים יציבים של הלופוגינון ושל נגזרות קווינזולינון אחרות
EP1558261A4 (en) * 2002-10-31 2008-06-04 Israel State CHINAZOLINONE COMPOSITIONS TO REGULATE GENE EXPRESSION IN CONNECTION WITH PATHOLOGICAL PROCESSES
US7816347B2 (en) * 2004-12-15 2010-10-19 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
US20080255165A1 (en) * 2005-02-23 2008-10-16 Mordechai Erez Pharmaceutical Compositions of the Isolated D-Enantiomer of the Quinazolinone Derivative Halofuginone
AU2006267841B2 (en) * 2005-07-07 2011-12-15 Yissum Research Development Company Of The Hebrew University Of Jerusalem Nucleic acid agents for downregulating H19, and methods of using same
US20070160640A1 (en) * 2006-01-12 2007-07-12 Eun-Hyun Jang Halofuginone delivering vascular medical devices
EP2010136B1 (en) * 2006-04-10 2012-09-12 The President and Fellows of Harvard College Methods for modulating formation and progression of cellulite
CN101652150B (zh) * 2006-12-01 2013-12-11 韦克福里斯特大学健康科学院 结合胶原抑制剂的医疗装置
US20100086526A1 (en) 2007-01-16 2010-04-08 Abraham Hochberg Nucleic acid constructs and methods for specific silencing of h19
WO2008087650A2 (en) 2007-01-21 2008-07-24 Agricultural Research Organization Composition and method for treating or preventing skeletal muscle fibrosis
WO2009002808A2 (en) 2007-06-22 2008-12-31 Arqule, Inc. Quinazolinone compounds and methods of use thereof
WO2009023267A2 (en) * 2007-08-15 2009-02-19 President And Fellows Of Harvard College Methods for modulating development and expansion of il-17 expressing cells
US9284297B2 (en) 2008-08-11 2016-03-15 President And Fellows Of Harvard College Halofuginone analogs for inhibition of tRNA synthetases and uses thereof
US8357692B2 (en) 2010-06-20 2013-01-22 Washington University Methods of treatment of bone degenerative diseases
CA2861840C (en) 2012-01-13 2020-12-15 President And Fellows Of Harvard College Halofuginol derivatives and their use in cosmetic and pharmaceutical compositions
WO2015034330A1 (ko) * 2013-09-09 2015-03-12 가톨릭대학교 산학협력단 헬로퓨지농을 유효성분으로 포함하는 골질환 치료 또는 예방용 조성물
CN105497091B (zh) * 2016-01-05 2020-01-24 香港浸会大学 一种用于抗癌的常山酮青蒿倍半萜内酯类化合物的组合物及其应用
EP3801525A4 (en) 2018-06-08 2022-03-23 The General Hospital Corporation PROLYL TRNA SYNTHETASE INHIBITORS

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3320124A (en) 1964-07-20 1967-05-16 American Cyanamid Co Method for treating coccidiosis with quinazolinones
DE2934069A1 (de) * 1979-08-23 1981-03-12 Hoechst Ag, 6000 Frankfurt Mittel gegen theileriosen und seine verwendung.
CA2113229C (en) * 1994-01-11 1999-04-20 Mark Pines Anti-fibrotic quinazolinone-containing compositions and methods for the use thereof
IL110831A (en) 1994-08-31 1998-12-27 Hadasit Med Res Service Pharmaceutical compositions containing quinazolinone derivatives for preventing restenosis
IL114951A (en) * 1995-08-15 1999-08-17 Hadasit Med Res Service Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6028075A (en) * 1997-02-11 2000-02-22 Pines; Mark Quinazolinone containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies

Also Published As

Publication number Publication date
EP1007044B1 (en) 2007-07-18
EP1007044A1 (en) 2000-06-14
IL131349A0 (en) 2001-03-19
CA2280850C (en) 2004-01-13
ATE367158T1 (de) 2007-08-15
US6420371B1 (en) 2002-07-16
US6028075A (en) 2000-02-22
KR100518106B1 (ko) 2005-10-04
KR20000070996A (ko) 2000-11-25
DE69838099T2 (de) 2008-04-30
EP1007044A4 (en) 2001-03-07
AU6004998A (en) 1998-08-26
JP2001518075A (ja) 2001-10-09
DE69838099D1 (de) 2007-08-30
USRE39574E1 (en) 2007-04-17
AU738516B2 (en) 2001-09-20
ES2290983T3 (es) 2008-02-16
WO1998034613A1 (en) 1998-08-13
CA2280850A1 (en) 1998-08-13

Similar Documents

Publication Publication Date Title
EP1007044B1 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating malignancies
KR101644440B1 (ko) 개선된 혈관신생 억제용 펩티드와 이를 유효성분으로 함유하는 혈관신생과 관련된 질환의 예방 및 치료용 조성물
Joussen et al. Inhibition of inflammatory corneal angiogenesis by TNP-470
AU705955B2 (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization and for treating human malignancies
JP2005537282A (ja) セファロタキシンアルカロイドによる血管新生抑制、並びにその誘導体、組成物、および使用方法
US6090814A (en) Quinazolinone-containing pharmaceutical compositions for prevention of neovascularization
US6211188B1 (en) Treatment of skin disorders
AU2007335963A1 (en) Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature
WO2003074074A1 (en) COMPOSITIONS COMPRISING Nm23 PROTEIN FOR THE USE OF MATRIX METALLOPROTEINASE INHIBITOR AND ANGIOGENESIS INHIBITOR
KR20210020849A (ko) 크리소파놀을 포함하는 난소암 또는 유방암의 예방 또는 치료용 약학적 조성물
IL112125A (en) Quinazolinone-containing pharmaceutical compositions
KR20210062449A (ko) 프리마퀸 디포스페이트와 그 타겟으로 usp1의 혈관누수차단 효과
US7709538B2 (en) ST104P, an anti-angiogenic agent
CN118526495A (zh) 达比加群酯在制备治疗白血病的药物中的应用
WO2009068906A2 (en) Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2002051423A1 (fr) Inhibiteurs d'angiogénèse
WO2005009461A1 (en) Factor vii activating protease (fsap) polypeptides for the treatment of angiogenesis-related disorders

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees